Jfl Life Sciences Limited — Board Meeting, 28-06-2025: Outcome of Board Meeting

JFL Life Sciences has announced a board meeting approving audited consolidated financial results for FY25. Revenue grew to ₹82.05 Cr from ₹46.55 Cr last year, driven by strong operational performance in pharmaceuticals manufacturing. Profit before tax jumped to ₹6.14 Cr versus ₹3.80 Cr, while net profit stood at ₹4.46 Cr compared to ₹2.52 Cr previously. The company declared bonus shares in a 2:1 ratio during the period, strengthening shareholder value. Cash flow from operations remained healthy at ₹8.20 Cr. JFL Life Sciences continues to focus on scaling its core pharma business, backed by a clean audit opinion with no qualifications.